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Resistina b s t r a c t
Background: The renin-angiotensin-system (RAS), endothelial dysfunction and sympathetic nervous sys-
tem are mechanistic risk factors of hypertension. The study sought to elucidate the interplay of adipoki-
nes in the pathogenesis of essential hypertension.
Methodology: This comparative cross-sectional study recruited 200 confirmed hypertensive patients
from the KATH and 50 age-matched normotensives. Participants’ blood pressures, anthropometric and
socio-demographic information were voluntarily obtained. Serum levels of adiponectin, leptin and resis-
tin of the participants were quantified using the ELISA. Renal function, lipid profile and glycemic status of
all subjects were also analyzed.
Results: Hypertensive patients showed a significantly higher anthropometric indices of adiposity
compared to normotensives, CI (p < 0.0001), BAI (p < 0.0001) and AVI (p = 0.002). Adiponectin levels
(p < 0.0001) were significantly lower in the hypertensive relative to the normotensives. Furthermore, sig-
nificantly higher concentrations of serum leptin (p = 0.016) and the leptin-adiponectin ratio (p = 0.001)
were observed among the hypertensive compared to the normotensives. The study further observed a
direct association between serum leptin and weight (r = 0.111, p = 0.022), BMI (r = 0.129, p = 0.009)
and WHtR (r = 0.098, p = 0.045) but inverse relationship with height (r = 0.134, p = 0.006) among the
hypertensive. Serum leptin has a significant negative correlation with HDL-C among the hypertensive
(r = 0.174, p = 0.013). The fully aOR for hypertension as predicted by resistin and adiponectin were
1.12 (95% Cl, 1.02–1.25); p = 0.019) and 0.93 (95% Cl, 0.91–0.95); p = 0.0001) respectively.
Conclusion: We found that elevations in serum levels of leptin and resistin, and low levels of adiponectin
may play a role in the pathogenesis of essential hypertension. Therefore, adipokines may offer themselves
as potential indices for early and accurate detection of high blood pressure. At the same time our present
results also confirm the conclusions with respect to correlation of leptin and obesity. Further longitudinal
studies in a larger population are warranted to investigate the physiological and pathological functions of
adipokines in hypertension.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypertension a global health concern has reached pandemic
levels and is often associated with high morbidity and mortality
rates that negatively impact on the public health and socio-
economic conditions.1 Essential hypertension has no specific
underlying medical cause and accounts for nearly 90–95% of all
diagnosed cases.2 It has been confirmed that hypertension was
the leading cause of cardiovascular mortality in 2013.3 Increasing
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factors of hypertension in recent times.4 The highest estimated
prevalence of hypertension in Africa has been pegged at 46%
among adults, aged 25 years and above, while the Americans have
the lowest prevalence of 35%.1 Similarly, according to WHO 2014
annual report, outpatient (OPD) cases of hypertension in Ghana
rose from 799,028 in 2011 to 830,620 in 2014 and is on record
as the highest among the non-communicable.5 In Ghana,
hypertensive-associated renal disease is a common complication
both in Kumasi and Accra.6
Hypertension has been shown to play a very active role in the
incidence metabolic syndrome.7 Metabolic syndromes is a group
of conditions characterized by high risk for heart disease,
hyperglycemia, raised triglyceride/and free fatty acids levels, low
HDL-cholesterol concentration and excessive abdominal fat.8
These conditions are associated with an increased or abnormal
fat mass of adipose tissue as seen in obesity and dyslipidemia.
Adipokines have been showed to contribute to the risk of hyper-
tension, for example, elevated levels of leptin have been proposed
to play a role in the pathogenesis of obesity-associated hyperten-
sion. Moreover, leptin is one of the major adipocyte hormones
and a principal determinant of bodyweight, energy metabolism
and the occurrence of obesity and its related disorders in human.9
Adiponectin also contributes significantly to the risk factors of
hypertension namely endothelium dysfunction (ED), renin-
angiotensin-system (RAS) and sympathetic nervous system
(SNS).10 Most studies on hypertension in Ghana have mostly been
on the behavioural and socioeconomic factors and other related
diseases. This study sought to assess the interplay of adipokines
in the pathogenesis of essential hypertension in a Ghanaian
setting.2. Patients and methods
2.1. Study design and setting
A comparative cross-sectional study conducted among con-
firmed hypertensive patients from the Hypertension Unit of the
Komfo Anokye Teaching Hospital (KATH), Ghana and age-
matched normotensives from September 2012 to March 2014.
KATH is a tertiary referral teaching hospital located in Kumasi,
the regional capital of the Ashanti region in Ghana with a total pro-
jected population of 4,780,380 according to the Ghana Statistical
Service, 2010. It is the second largest Hospital in Ghana. The geo-
graphical location of this teaching hospital, coupled with a well-
defined road network makes this facility accessible to patients
within the catchment area of the hospital.
2.2. Ethical consideration
This study was approved by the Committee on Human
Research, Publication and Ethics (CHRPE) of School of Medical
Sciences, KNUST and KATH. The subjects were adequately
informed of the purpose, procedures, nature, risks and minimal
discomfort of the study. Participants were coded and assured of
strict anonymity, confidentiality and the freedom to exit or decline
participation at any time without penalty.
2.3. Study population and subject recruitment
Using a simple random sampling technique, two 200 confirmed
hypertension patients aged  30 years attending the Hypertension
clinic, KATH and 50 age-matched normotensives. Participants who
were all clinically stable voluntarily consented to the study.
Individuals with secondary hypertension, diabetes, cardiovasculardiseases, kidney or liver dysfunction as well as pregnant women
were essentially excluded from the study. Participants’ blood pres-
sures and anthropometric as well as their socio-demographic and
treatment information were voluntarily obtained.
2.4. Blood pressure measurement
Systolic and diastolic blood pressures of the study subjects were
taken by two experienced senior nurses at the Hypertension clinic.
Each participant was seated quietly and relaxed in an armchair
with feet on the floor and arm supported at the heart level for at
least 5 min. The brachial artery was located andmercury sphygmo-
manometer (Accoson, UK) with suitable cuff bladder size of
13 cm  23 cm was used to encircle an upper arm of each partici-
pant. Cuff bladder which was connected to column of mercury
with graduated scale, was inflated to exert pressure on the large
brachial artery until the blood flow stopped and the pressure
slowly released and, with the help of a stethoscope listened to
the pulse for the determination of both systolic and diastolic pres-
sures readings on the scale in millimeters of mercury (mmHg).
Three measurements were taken for each participant at one-
minute interval and then the average used as the mean systolic
and diastolic pressures that were recorded into the data.2.5. Anthropometric measurements
Body weight, expressed in 0.1-kg intervals, was measured at
fasting state in the morning using automated scale. Portable Height
Rod Stadiometers were used for body height to the nearest cen-
timeters. The subject stood straight, with feet placed together
and flat on the ground, heels, buttocks and scapulae against the
vertical backboard, and arms loose and relaxed with the palms
facing medially. Their heads were carefully positioned in the
Frankfurt plane, with the lower margins of the orbit in the same
horizontal plane as the upper margin of the external auditory mea-
tus. BMI was calculated as body weight divided by height squared
(Kg/m2).
HC was measured at the level of maximal gluteal protrusion and
waist circumference at the midpoint between the anterior superior
iliac crest and the lowest rib using a tape measure while the sub-
ject stood with feet 25–30 cm apart. The tape measure was placed
directly on the skin. Patients were allowed to breathe out normally
and measurements were taken. The tape was held lightly so as not
to compress the skin. WHtR and WHR were calculated as WC (cm)
divided by Ht (cm) and HC respectively. Body Adiposity Index (BAI)
was calculated as the size of the hips compared to the patient’s
height. BAI ¼ HipC cmð Þ~A  Height mð Þ½ 1:5  18
The conicity index (CI) was determined from the
measurements of weight, height and waist circumference.






Abdominal volume index (AVI) was derived from the measure-
ments of waist circumference (WC) and hip circumferences (HC)
AVI ¼ 2½waistCðcmÞ2þ0:7½waistC cmð ÞhipCðcmÞ21000
Visceral Adiposity Index (VAI) uses the study participant’s waist
circumference (WC), BMI, triglyceride (TG) and HDL-C levels
VAI for females ¼ WC
36:58







VAI for males ¼ WC
39:68







Atherogenic index (AI) utilizes triglyceride and HDL-C concen-
trations in the formula
Table 1
Biochemical parameters and adipokines between hypertensive and normotensive.
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FBG (mmol/L) 5.9 ± 2.1 5.2 ± 0.71 0.0175
Serum creatinine
(mmol/L)
70.1 ± 31.2 67.9 ± 18.5 0.6241
serum urea
(mmol/L)
3.9 ± 1.7 3.4 ± 0.8 0.0378
TC (mmol/L) 5.5 ± 1.4 4.2 ± 1.0 <0.0001
TG (mmol/L) 1.3 ± 0.7 1.2 ± 0.7 0.3218
HDL (mmol/L) 1.5 ± 0.4 1.3 ± 0.5 0.0427
LDL (mmol/L) 3.4 ± 1.2 2.4 ± 0.9 <0.0001
Atherogenic Index 1.0 ± 0.7 1.1 ± 0.9 0.8054
Coronary risk 3.8 ± 0.1 3.2 ± 0.5 0.0367
SBP (mmHg) 150.0 ± 22.2 120.9 ± 10.2 <0.0001
DBP (mmHg) 90.1 ± 10.3 75.9 ± 8.3 <0.0001
Resistin (mg/l) 7.3 ± 0.25 6.7 ± 0.12 0.22682.6. Biochemical analysis
The stored frozen plasma and sera of blood samples of the par-
ticipants were stalled to room temperature and analyzed quantita-
tively for various biochemical assays specifically glucose,
creatinine, urea, total cholesterol, triglycerides and HDL-
cholesterol on a chemistry auto-analyzer, COBAS INTEGRA 400
plus automated chemistry analyzer (Roche Diagnostics GmbH,
Mannheim, Germany) using the manufacturer’s protocol. Serum
levels of adiponectin, leptin and resistin of the participants were
quantified using the enzyme-linked immunosorbent assays
(ELISA).Adiponectin
(pg/mL)
157.3 ± 0.52 189.7 ± 0.87 <0.0001










0.05 ± 0.01 0.04 ± 0.004 0.0030
Leptin/
adiponectin
0.008 ± 0.006 0.004 ± 0.0008 0.0010
Anthropometric
indices
BMI (Kg/m2) 28.9 ± 6.6 27.2 ± 11.8 0.2867
CI 1.27 ± 1.6 1.08 ± 1.8 0.4740
BAI 32.4 ± 7.7 24.5 ± 11.6 <0.0001
AVI 17.8 ± 6.0 12.5 ± 4.9 <0.0001
VAI 5.2 ± 0.3 3.0 ± 0.5 <0.00012.7. Statistical analysis
Data was entered into Microsoft excel and analyzed using SPSS
version 23. Continuous variables were expressed as mean ± SD for
normal distributed data and median (inter-quartile range), while
comparisons between confirmed hypertensive and normotensives
were performed using parametric and non-parametric analysis
where appropriate. Association of serum adipokines with clinical
variables, anthropometrics, and blood lipid profiles among hyper-
tensive were analyzed using partial Pearson correlation. P-value
less < 0.05 were considered statistically significant.FBG: fasting blood glucose; TC: total cholesterol; TG: triglyceride; HDL: high den-
sity lipoprotein; LDL: low density lipoprotein, BMI = body mass index, CI = conicity
index, BAI = body adiposity index, VAI = visceral adiposity index, AVI = abdominal
volume index p < 0.05 was considered statistically significant.3. Results
Serum adiponectin concentration was significantly lower in
hypertensives than normotensives (p < 0.001). Contrary, serum
leptin concentration was significantly higher in both systolic and
diastolic pressures of hypertensives than the normotensive sub-
jects (p < 0.0001). It was also observed that the mean resistin levels
were higher in hypertensives though not statistically significant
(p = 0.2668). The hypertension patients have higher serum concen-
trations of lipid profile parameters namely total cholesterol
(TC, p < 0.0001), triglycerides (TG), LDL-C (p < 0.0001) and HDL-C
(p = 0.0427) than the control subjects. Moreover, the serum urea
levels (p = 0.0378) and fasting plasma glucose (FBG) concentration
(p = 0.0175) of hypertensive subjects were significantly higher
than the control subjects [Table 1].
Using non-parametric analysis, median BMI (p < 0.0001), conic-
ity index (p = 0.0297), body adiposity index (p < 0.0001) and
abdominal volume index (p = 0.0010) of the female hypertension
subjects were statistically significant higher compared to their
male counterparts. The median creatinine (p < 0.0001) and urea
concentrations (p = 0.0257) were significantly higher in males
compared to females. However, median TC (p = 0.0022), HDL-C
(p = 0.003), LDL-C (p = 0.0157) were significantly higher in females
compared to that of the male subjects. However, no statistical sig-
nificant difference was observed between male and female in rela-
tion to the concentrations of adipokines (p > 0.05) (see Table 2).
Serum resistin and leptin concentrations showed significant
and negative correlation with urea (r = 0176, p = 0.013) and
HDL-C (r = 0.174, p = 0.013) respectively in both age and sex-
adjusted models. Positive correlation was observed between leptin
and triglyceride (r = 0.012, p = 0.863). Serum levels of resistin
showed negative correlation with FBS (r = 0.019, p = 0.785), crea-
tinine (r = 0.089, p = 0.238), TC (r = 0.036p = 0.611) and LDL-C
(r = 0.077, p = 0.278) and CR (r = 0.054, p = 0.444). Leptin also
has statistically insignificant and positive correlation with the bio-
chemical variables and coronary indices [Table 3].As shown in Table 4, there was a significantly positive
correlation between serum leptin and weight (r = 0.111, p = 0.022),
BMI (r = 0.126, p = 0.009), and WHtR (r = 0.098, p = 0.045) among
hypertension patients. Conversely, a weak, but significant negative
correlationwas observed between serum levels of leptin and height
(r = 0.134, p = 0.006). No statistically significant correlations were
observed for resistin and adiponectin with anthropometric indices
(p > 0.05).
After controlling for age, gender and BMI, the fully adjusted
odds ratio (aOR) for hypertension as predicted by resistin and
plasma adiponectin were 1.128 (95% CI, 1.020–1.247; p = 0.019)
and 0.933 (95% CI, 0.909–0.953; p < 0.0001) respectively. This indi-
cates that there was a 12.8% increase in the odds of having hyper-
tension for each 1 lg/L increase in resistin and 6.7% decrease in the
odds of having hypertension for each 1 pg/ml increase in serum
adiponectin. Moreover, the fully adjusted odds ratio (OR) for
hypertension as predicted by systolic and diastolic were 1.097
(95% CI, 1.05–1.14; p < 0.0001) and 1.13 (95% CI, 1.06–1.21;
p = 0.001) respectively. This observation suggests that, there were
9.7% and 13.1% increase in the odds of having hypertension for
each mmHg increase in systolic and diastolic pressures. However,
none of the biochemical assays as well as the atherogenic index
has any significant association with the risk of hypertension
[Table 5].4. Discussion
Adipokines are known to contribute to the regulation of varied
biological processes, including inflammation, immune function
and metabolic syndrome. They also play various important roles
in vascular biology, hematopoiesis and cell proliferation as well
Table 2
Comparison of variables between male and female hypertensive subjects.
Variables Female (n = 137) Male (n = 63) p-value
Blood pressure









BAI 35.89(30.45–42.49) 26.95(24.04–31.43) <0.0001
AVI 18.53(14.53–22.9) 15.51(13.80–18.05) 0.0010
VAI 3.26(1.89–4.63) 3.13(1.76–4.50) 0.0600
Biochemical parameters




Urea(mmol/L) 3.40(2.58–4.56) 3.87(3.04–4.89) 0.0257
TC(mmol/L) 5.43(4.68–6.23) 4.89(4.14–5.60) 0.0022
TG (mmol/L) 1.14(0.80–1.60) 1.09(0.78–1.46) 0.5114
HDL-C(mmol/L) 1.42(1.22–1.83) 1.28(0.97–1.56) 0.003
LDL-C(mmol/L) 3.40(2.65–4.05) 2.80(2.30–3.80) 0.0157
Cardiovascular
risks



















R/A 0.042(0.033–0.060) 0.042(0.034–0.052) 0.9618
L/A 0.007(0.006–0.012) 0.007(0.005–0.008) 0.1027
FBG: fasting blood glucose; TC: total cholesterol; TG: triglyceride; HDL: high den-
sity lipoprotein; LDL: low density lipoprotein, BMI = body mass index, CI = conicity
index, BAI = body adiposity index, VAI = visceral adiposity index, AVI = abdominal
volume index p < 0.05 was considered statistically significant, L/A = Leptin/Adipo-
nectin, R/A = Resistin/Adiponectin.
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subjects had significantly lower plasma concentration of adiponec-
tin compared their counterpart normotensive. Furthermore, adipo-
nectin levels were significantly associated with reduced odds for
hypertension. This observation confirms the fact that low plasma
levels of adiponectin impact a negative effect on cardiac output.12
In addition, various studies have confirmed this observation.13,14
Moreover, plasma leptin levels of hypertensive subjects were
significantly higher compared to the normotensives. This observa-
tion is plausible considering the biogenic role of leptin in the
sympathetic nervous system.15 Plasma leptin transverses theTable 3
Partial Pearson correlation of serum adipokines with biochemical markers of hypertension
Variables Resistin (mg/l)
r p-value
FBS (mmol/L) 0.019 0.785
Creatinine (mmol/L) 0.089 0.239
Urea (mmol/L) 0.176 0.013
TC (mmol/L) 0.036 0.611
TG (mmol/L) 0.092 0.197
HDL-C (mmol/L) 0.061 0.39
LDL-C (mmol/L) 0.077 0.278
CR 0.054 0.444
AI 0.550 0.455
CR: Coronary risk AI: Atherogenic index.
Correlation is significant at the 0.05 level (2-tailed). r: correlation coefficient; TC: tot
lipoprotein.blood-brain-barrier and binds to its receptors in various regions
of the central nervous system (CNS), including the hypothalamus
and brainstem. Indeed, leptin has been shown to activate neural
pathways that decrease appetite but increase SNS activity and
energy expenditure.16 Hyperleptinemia contributes immensely to
hyperactivity of the sympathetic nervous system and subsequently
increase in blood pressure.17
Various studies have also confirmed the contributory role of
resistin in adipogenesis and inflammation.18 Results from this
studies showed that hypertensive subjects had higher levels of
resistin compared to the normotensives. This finding is consistent
with reports from a study conducted in Greece which demon-
strated significant higher levels of resistin in patients with essen-
tial hypertension compared to normotensives.19 Furthermore,
plasma resistin was significantly associated with higher odds for
hypertension after controlling for age, gender and BMI (Table 5).
Several mechanisms contribute to the possible involvement of
resistin in the pathogenesis of hypertension including inflamma-
tion.20 As a pro-inflammatory adipokine, resistin is known to be
actively involved in the vascular inflammation. It is of interest to
also note that inflammation of the vascular wall plays an important
role in the pathogenesis and progression of atherosclerosis, cardio-
vascular disease and hypertension.21 It has been proven that essen-
tial hypertension is characterized by vascular wall inflammation
which causes resistance to the blood flow. At the functional level,
resistin induces the expression of the pro-inflammatory cytokines
IL-6 and TNF-a, probably via the NF-ĸB pathway in the human
mononuclear cells.22
However, that the antagonistic action of resistin on insulin sig-
naling is achieved by the involvement of two signaling pathways.
The first signaling pathway, serum resistin inhibits the AMPK sig-
naling pathway in the liver and the muscle.23 This action of resistin
induces the expression of suppressor of cytokine signaling(SOCS) 3
in adipocytes, a signaling molecule noted for its antagonistic effect
on insulin signaling.24 Thus, the probability of hypertensive
patients developing diabetes is enhanced by the high plasma con-
centration of resistin.25,26
It was further observed in this current study that, the hyperten-
sive subjects with elevated levels of resistin were dyslipidemic
with raised levels of serum TC and LDL-C as against the normoten-
sive group. Studies have confirmed that resistin increases the intra-
cellular availability of non-esterified fatty acids in human
macrophages.27 The contributory roles exhibited by resistin and
leptin in the aetiogenesis of hypertension as proffered in this study,
thus stresses the importance of including leptin and resistin to the
routine repertoire of laboratory investigations for hypertensive
patients.
We found a statistically significant and positive correlation
between serum leptin concentrations and weight, BMI and WHtR..
Adiponectin (pg/ml) Leptin (mg/l)
r p-value r p-value
0.105 0.140 0.029 0.687
0.044 0.533 0.086 0.226
0.058 0.416 0.084 0.239
0.054 0.444 0.068 0.336
0.076 0.286 0.012 0.863
0.053 0.457 0.174 0.013
0.057 0.426 0.08 0.262
0.081 0.254 0.100 0.157
0.080 0.261 0.026 0.712
al cholesterol; TG: triglyceride; HDL: high density lipoprotein; LDL: low density
Table 4
Partial Pearson correlation of serum adipokines with anthropometric indices among hypertensive patients.
Resistin (mg/l) Adiponectin (pg/ml) Leptin (mg/l)
r p-value r p-value r p-value
Weight (kg) 0.066 0.35 0.06 0.398 0.111 0.022
Height (m) 0.071 0.32 0.066 0.353 0.134 0.006
BMI (kg/m2) 0.043 0.545 0.081 0.256 0.126 0.009
WC (cm) 0.019 0.789 0.01 0.885 0.005 0.942
Hip C (cm) 0.032 0.657 0.028 0.694 0.037 0.600
WHR 0.015 0.828 0.002 0.982 0.051 0.472
WHtR 0.003 0.964 0.008 0.905 0.098 0.045
BAI 0.005 0.949 0.006 0.931 0.043 0.545
CI 0.030 0.670 0.065 0.362 0.100 0.161
AVI 0.028 0.690 0.011 0.872 0.005 0.945
VAI 0.042 0.565 0.08 0.124 0.019 0.543
Correlation is significant at the 0.05 level (2-tailed). r: correlation coefficient. BMI: Body mass index; WC: waist circumference; Hip C: hip circumference; WHR: waist-to-hip
ratio; WHtR: waist-to-height ratio BAI: Body Adiposity index CI: Conicity index AVI: Abdominal volume index; VAI: Visceral adiposity index.
Table 5
Regression analysis model of the risk of hypertension using adipokines, coronary and
biochemical indices.
Variables Adjusted OR 95% CI for OR P-value
Systolic blood pressure 1.10 (1.05–1.14) <0.0001
Diastolic blood pressure 1.13 (1.06–1.21) 0.001
FBS(mmol/L) 1.11 (0.72–1.72) 0.646
Creatinine(mmol/L) 1.00 0.97–1.02) 0.953
Urea(mmol/L) 1.50 (0.92–2.41 0.099
TC(mmol/L) 2.36 (0.002–233.51) 0.710
TG(mmol/L) 0.39 0.01–3.85) 0.423
HDL(mmol/L) 1.16 (0.01–126.5) 0.952
LDL(mmol/L) 0.67 (0.007–67.0) 0.865
AI 1.20 (0.92–2.06) 0.780
Age (per year) 1.026 (1.002–1.051) 0.035
Gender (female) 0.616 (0.321–1.181) 0.145
BMI (kg∕m2) 1.085 (1.021–1.142) 0.005
WHR 14.612 (0.874–24.42) 0.062
WHtR 0.031 (0.002–1.616) 0.085
CI 1.025 (0.99–1.06) 0.104
BAI 1.057 (0.99–1.13) 0.091
AVI 1.098 (0.94–1.28) 0.240
Resistin ((mg/L) 1.128 (1.020–1.247) 0.019
Adiponectin(pg/mL) 0.933 (0.909–0.958) <0.0001
Leptin(mg/L) 0.908 (0.657–1.253) 0.556
OR: Odds ratio; CI: confidence interval. Statistical significant difference (p < 0.05).
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numerous studies that have reported that leptin concentration is
closely associated with BMI. Moreover, leptin also plays a signifi-
cant role in the regulation of feeding behaviour and arterial
hypertension.28
Although, the findings of this study are novel, there were some
limitations. Despite our extensive effort to rule out confounding
factors which may interfere with the adipokines such as adiponec-
tin, resistin and leptin, there may be possible unforeseen con-
founders which were not controlled. In addition, this was a
cross-sectional comparative study conducted with small sample
size which limited our ability to explain the causal correlations
between adipokines and hypertension. However, we are confident
in our findings will be a baseline for further probing.5. Conclusion
We found that elevations in serum levels of leptin and resistin,
and low levels of adiponectin may play a role in the pathogenesis
of essential hypertension. Therefore, adipokines may offer them-
selves as potential indices for early and accurate detection of high
blood pressure. At the same time our present results also confirmthe conclusions with respect to correlation of leptin and obesity.
Further longitudinal studies in a larger population are warranted
to investigate the physiological and pathological functions of
adipokines in hypertension.
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